Statement of Retraction: Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients.

IF 2.5 4区生物学 Q3 MICROBIOLOGY Future microbiology Pub Date : 2025-01-09 DOI:10.1080/17460913.2025.2451540

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

撤回声明：以伊维菌素为基础的多种药物治疗重症缺氧门诊COVID-19患者的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future microbiology 生物-微生物学

CiteScore

4.90

自引率

3.20%

发文量

134

审稿时长

6-12 weeks

期刊介绍： Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.

期刊最新文献

Trichosporon asahii: emerging challenges in pathogenesis and drug resistance. Rethinking natural product discovery to unblock the antibiotic pipeline. Evaluation of the antibacterial properties of four bioactive biomaterials for chronic wound management. Statement of Retraction: Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients. A new N-acylhydrazone oxadiazole derivative with activity against mycobacteria.